Download PDF
Thromb Haemost 2017; 117(01): 57-65
DOI: 10.1160/TH15-08-0686
Coagulation and Fibrinolysis
Schattauer GmbH

Epidemiology of first and recurrent venous thromboembolism in patients with active cancer

A population-based cohort study
Alexander T. Cohen
1   Guy’s and St Thomas’ NHS Foundation Trust Hospitals, London, UK
,
Anja Katholing
2   Independent Researcher, Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany
,
Stephan Rietbrock
2   Independent Researcher, Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany
,
Luke Bamber
3   Bayer Pharma AG, Wuppertal, Germany
,
Carlos Martinez
2   Independent Researcher, Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany
› Author Affiliations
Further Information

Publication History

Received: 27 August 2016

Accepted after major revision: 17 September 2016

Publication Date:
01 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Population studies on the incidence of venous thromboembolism (VTE) in patients with active cancer are limited. An observational cohort study was undertaken to estimate the incidence of first and recurrent VTE. The source population consisted of all patients in the UK Clinical Practice Research Datalink, with additional information on hospitalisation and cause of death, between 2001 and 2011. A cancer-related clinical diagnosis or therapy within the 90 days before or after a VTE constituted an active-cancer-associated VTE. Incidence rates of first VTE among patients with active cancer and incidence rates of recurrent VTE during the 10-year observational period after a first VTE event were estimated. Incidence rates of all-cause mortality and age- and gender-specific mortality were also calculated. There were 6,592 active-cancer-associated VTEs with a total of 112,738 cancer-associated person-years of observation. The incidence rate of first VTE in patients with active cancer was 5.8 (95 % confidence interval 5.7–6.0) per 100 person-years. A first VTE recurrence was observed in 591 patients. The overall incidence rate for recurrence was 9.6 (95 % confidence interval 8.8–10.4) per 100 person-years, with a peak at 22.1 in the first six months. Recurrence rates were similar after initial pulmonary embolism and after initial deep-vein thrombosis. The mortality risk after VTE was considerable, with 64.5 % mortality after one year and 88.1 % after 10 years. VTE in patients with active cancer is common and associated with high recurrence and mortality rates. Efforts are needed to prevent VTE and reduce recurrence, especially in the first year after VTE diagnosis.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Active cancer - venous thromboembolism incidence - recurrence - mortality

 

  • References

  • 1 Chew HK, Wun T, Harvey D. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
    CrossrefPubMedGoogle Scholar
  • 2 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembol-ism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Ed). Chest 2008; 133: 381S-453S.
    CrossrefPubMedGoogle Scholar
  • 3 Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J 1991; 302: 709-711.
    CrossrefPubMedGoogle Scholar
  • 4 Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-579.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Stein PD, Beemath A, Meyers FA. et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119: 60-68.
    CrossrefPubMedGoogle Scholar
  • 6 Chee CE, Ashrani AA, Marks RS. et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 2014; 123: 3972-3978.
    CrossrefPubMedGoogle Scholar
  • 7 Cohen AT, Agnelli G, Anderson FA. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Svendsen E, Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 1989; 42: 805-809.
    CrossrefPubMedGoogle Scholar
  • 9 Heit JA, Silverstein MD, Mohr DN. et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-463.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011; 117: 1334-1349.
    CrossrefPubMedGoogle Scholar
  • 11 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e419S-e494S.
    CrossrefPubMedGoogle Scholar
  • 12 Martinez C, Cohen AT, Bamber L. et al. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost 2014; 112: 255-263.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Medicines & Healthcare products Regulatory Agency, National Health Service National Institute for Health Research. Clinical Practice Research Datalink. Observational data Available at: http://www.cprd.com/ObservationalData/CodedData.asp Accessed June 2, 2015
    PubMedGoogle Scholar
  • 14 Medicines & Healthcare products Regulatory Agency, National Health Service National Institute for Health Research. Clinical Practice Research Datalink. Central mortality data Available at: http://www.cprd.com/dataAccess/ Accessed June 2, 2015
    PubMedGoogle Scholar
  • 15 Satagopan JM, Ben Porat L, Berwick M. et al. A note on competing risks in survival data analysis. Br J Cancer 2004; 91: 1229-1235.
    CrossrefPubMedGoogle Scholar
  • 16 Heit JA, O’Fallon WM, Petterson TM. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-1248.
    CrossrefPubMedGoogle Scholar
  • 17 Walker AJ, Card TR, West J. et al. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer 2013; 49: 1404-1413.
    CrossrefPubMedGoogle Scholar
  • 18 Douketis J, Tosetto A, Marcucci M. et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. Br Med J 2011; 342: d813.
    CrossrefPubMedGoogle Scholar
  • 19 Prandoni P, Lensing AWA, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
    CrossrefPubMedGoogle Scholar
  • 20 Lee AY, Levine MN, Baker RI. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
    CrossrefPubMedGoogle Scholar
  • 21 Lee AY, Bauersachs R, Janas MS. et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013; 13: 284.
    CrossrefPubMedGoogle Scholar
  • 22 Prins MH, Lensing AWA, Brighton TA. et al. Oral rivaroxaban versus enoxapa-rin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 01: e37-e46.
    PubMedGoogle Scholar
  • 23 Lawrenson R, Todd JC, Leydon GM. et al. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000; 49: 591-596.
    PubMedGoogle Scholar
  • 24 Huerta C, Johansson S, Wallander MA. et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167: 935-943.
    CrossrefPubMedGoogle Scholar
  • 25 Naess IA, Christiansen SC, Romundstad P. et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 05: 692-699.
    CrossrefPubMedGoogle Scholar
  • 26 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
    CrossrefPubMedGoogle Scholar
  • 27 Dregan A, Moller H, Murray-Thomas T. et al. Validity of cancer diagnosis in a primary care database compared with linked cancer registrations in England. Population-based cohort study. Cancer Epidemiol 2012; 36: 425-429.
    CrossrefPubMedGoogle Scholar
  • 28 Cohen AT, Edmondson RA, Phillips MJ. et al. The changing pattern of venous thromboembolic disease. Haemostasis 1996; 26: 65-71.
    PubMedGoogle Scholar
  • 29 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389.
    CrossrefPubMedGoogle Scholar